Group 1 - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for any false records or omissions [2][3][6] - The company plans to propose a mid-term dividend distribution plan for 2025, contingent on achieving positive distributable profits and cash flow [7][8][9] - The board of directors supports the proposal to authorize the board to decide on the mid-term dividend distribution, aiming to simplify the process and enhance investor returns [11][12] Group 2 - The company has decided to renew the appointment of Tianjian Accounting Firm as the auditing institution for the 2025 fiscal year, pending approval from the shareholders' meeting [13][14][22] - Tianjian Accounting Firm has a good investor protection capability, with a cumulative professional risk fund and insurance compensation limit exceeding 200 million yuan [15] - The auditing committee has reviewed and approved the renewal of the auditing firm, confirming its independence and professional competence [21][22][37] Group 3 - The company plans to apply for a total credit limit of up to 3.5 billion yuan from banks for 2025, to support its development plans [26][28] - The guarantees provided by the company and its subsidiaries do not require any fees or counter-guarantees [26][29] - The board and supervisory board have approved the credit application and guarantee matters, which will be submitted to the shareholders' meeting for approval [35][37] Group 4 - The company intends to conduct forward foreign exchange settlement and sales business in 2025, with a maximum amount not exceeding 6 million USD or its equivalent in RMB [41][43] - The purpose of this business is to mitigate the adverse effects of exchange rate fluctuations on the company [41][43] - The board and supervisory board have approved the forward foreign exchange business, which does not require shareholder meeting approval [46][47] Group 5 - The company has changed its accounting policies in accordance with the Ministry of Finance's new regulations, effective from January 1, 2024, and December 6, 2024 [55][59] - This change does not require retrospective adjustments and will not affect the company's financial status or results [56][60] - The new accounting policies aim to ensure compliance with legal requirements and reflect the company's financial condition accurately [57][60]

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 注：除以上内容外，统一将 "股东大会"表述调整为"股东会"，"或"表述调整为"或者"；因删减和新增部 分条款，《公司章程》中原条款序号、援引条款序号按修订内容相应调整。 除上述条款进行修订外，其他条款保持不变。修订后的《公司章程》全文同日披露于上海证券交易所网 站（http://www.sse.com.cn）。本次修订《公司章程》尚需提交公司2024年年度股东大会审议，同时提 请股东大会授权公司管理层负责办理章程备案等相关事宜。上述变更最终以工商登记机关核准的内容为 准。 上述制度中，第1、2项制度修订需提交公司2024年年度股东大会审议；第3至5项制度修订、制定由董事 会审议批准。本次修订、制定的制度全文同日披露于上海证券交易所网站（http://www.sse.com.cn）。 特此公告。 雅戈尔时尚股份有限公司 董 事 会 二〇二五年四月二十四日 股票简称：雅戈尔 股票代码：600177 编号：临2025-019 雅戈尔时尚股份有限公司 三、相关制度修订、制定情况 根据《公司法》《证券法》《上市公司章程指引》《上市公司信息披露管理办法》《上市公司股东 ...

■ 登录新浪财经APP 搜索【信披】查看更多考评等级 履约能力分析：该企业经营情况和财务状况良好，能够履行与公司达成的各项协议，其应支付的款项形 成坏账的可能性很小。 2025年与该关联人进行的各类日常关联交易总额不超过64,350万元（不含税）。 2.武汉理工光科股份有限公司。法定代表人：江山。注册资本：9306.1959万元。住所：武汉市东湖开发 区武汉理工大学科技园。经营范围：一般项目：光纤传感、仪器仪表、光机电器件、计算机软、硬件等 技术及产品的开发、技术服务及咨询、开发产品制造、销售；承接自动化系统工程、计算机网络工程安 装、维护；自动化办公设备、机电设备、仪表及电子产品生产、销售；钢材、钢铁炉料、建筑材料、五 金交电、计算机销售；机械设备安装及维修；经营本企业自产产品及技术的出口业务；代理出口将本企 业自行研制开发的技术转让给其他企业所生产的产品；经营本企业生产、科研所需的原辅材料、仪器仪 表、机械设备、零配件及技术的进口业务；经营进料加工"三来一补"业务；消防器材开发研制、生产、 销售；消防工程设计、制造、安装；消防设备的销售；消防器材的维护及修理业务；电子专用设备（火 灾自动报警设备及消防联动 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：001270 证券简称：铖昌科技 公告编号：2025-024 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 □是 R否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 R是 □否 追溯调整或重述原因 □会计政策变更 □会计差错更正 □同一控制下企业合并 R其他原因 （二） 非经常性损益项目和金额 R适用 □不适用 单位：元 其他符合非经常性损益定义的损益项目的具体情况 □适用 R不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的 ...

Core Viewpoint - The company reported a significant decline in revenue and continued losses for the year 2024, with a net profit attributable to shareholders of -181.26 million yuan, indicating a challenging operational environment and the need for strategic adjustments [26][57]. Business Overview - The primary business of the company is in the hotel service industry, supplemented by various lifestyle services such as laundry, housekeeping, property management, and catering. The company operates under a light asset model, focusing on revitalizing heavy assets [3][4]. - The hotel segment generated revenue of 521.89 million yuan, a decrease of 15.40% compared to the previous year, attributed to poor market conditions and slow recovery in business and tourism demand [3]. - The lifestyle services segment accounted for 12.82% of total revenue, an increase of 3.57 percentage points year-on-year, indicating growth in this area despite challenges in the hotel sector [4]. Financial Performance - The company underwent a change in accounting policy regarding investment properties, shifting from a cost model to a fair value model to better reflect the true value of its assets [6]. - The company plans not to distribute cash dividends or issue bonus shares for 2024 due to negative retained earnings and to ensure sustainable operations [2][26]. - The 2025 financial budget anticipates a revenue increase to 720 million yuan, representing a 19% growth compared to 2024, although this remains uncertain due to various external factors [31]. Board Decisions - The board approved several key reports, including the 2024 annual report and the first quarter report for 2025, with some dissent from board members regarding the company's performance and strategic direction [9][21][26]. - A proposal for a comprehensive credit limit of up to 3.5 billion yuan was approved to support daily operations and reduce financing costs [34][35]. - The company is seeking to extend a financial assistance agreement with Hunan Xingxiang Investment Holding Group for 500 million yuan, which involves related party transactions [38]. Shareholder Meeting - The company will hold its 2024 annual shareholder meeting on May 15, 2025, to discuss various proposals, including the financial budget and related party transactions [62][64].

具体内容详细披露于2025年4月23日《中国证券报》《上海证券报》《证券时报》及上海证券交易所网 站（www.sse.com.cn）上的《关于会计政策变更的公告》（公告编号：2025-022）。 (十)审议通过了关于公司2024年度内部控制评价报告的议案 议案表决情况：同意11票、反对0票、弃权0票、回避0票 公司2024年度内部控制评价报告已经公司董事会审计委员会审议通过。 《2024年度内部控制评价报告》详细披露于2025年4月23日上海证券交易所网站（www.sse.com.cn）。 (十一)审议通过了关于公司2024年度财务报告内部控制审计报告的议案 议案表决情况：同意11票、反对0票、弃权0票、回避0票 公司2024年度财务报告内部控制审计报告已经公司董事会审计委员会审议通过。 《2024年度内部控制审计报告》详细披露于2025年4月23日上海证券交易所网站（www.sse.com.cn）。 (十二)审议通过了关于公司2024年度社会责任报告的议案 议案表决情况：同意11票、反对0票、弃权0票、回避0票 《2024年度社会责任报告》详细披露于2025年4月23日上海证券交易所网站（www.sse.c ...

Core Viewpoint - The company, Jilin Xidian Pharmaceutical Technology Development Co., Ltd., has released its annual report for 2024, highlighting its financial performance, business operations, and future development plans. The report indicates a focus on the research, production, and sales of chemical raw materials and formulations, particularly in the fields of iron supplementation and psychiatric medications [1][5]. Company Overview - The company primarily engages in the research, production, and sales of chemical raw materials and formulations, with a strong emphasis on iron supplementation, treatment of circulatory disorders, and psychiatric medications [5]. - As of the end of the reporting period, the company holds 25 registered formulation varieties (32 specifications) and 16 registered raw material drug approvals, focusing on anti-anemia, circulatory disorder treatments, and psychiatric medications [5]. Financial Highlights - The company has received a standard unqualified audit opinion from Rongcheng Accounting Firm for the financial report of the reporting period [3]. - The board of directors approved a profit distribution plan, proposing a cash dividend of 2.60 yuan per 10 shares (including tax), with no stock bonus or capital reserve transfer [4][9]. Shareholder Information - The company has no preferred shareholders and has disclosed the shareholding structure, including the top 10 shareholders [7][8]. Recent Developments - The company has received several approvals for new drug applications, including sodium hyaluronate eye drops and other formulations, indicating ongoing product development and regulatory compliance [8][65]. - The company has also obtained a patent for the application of rhizoma smilacis in preparing drugs for treating lymphatic reflux disorders [10][67]. Governance and Compliance - The company’s board and supervisory committee have ensured that the annual report and its summary are accurate and complete, with no misleading statements or omissions [11][18]. - The company has appointed Rongcheng Accounting Firm as its auditor for the year 2025, following a thorough review of the firm’s qualifications and capabilities [42][56].

登录新浪财经APP 搜索【信披】查看更多考评等级 5、企业名称：上海胤祺集成电路有限公司 统一社会信用代码：91310115350679893U 法定代表人：王建华 注册资本：壹仟万元整 注册地址：中囯（上海）自由贸易试验区新金桥路1888号36幢9层902单元 成立时间：2015年08月20日 经营范围：一般项目：集成电路芯片设计及服务；软件开发。（除依法须经批准的项目外，凭营业执照 依法自主开展经营活动）自主展示（特色）项目：人工智能理论与算法软件开发；技术服务、技术开 发、技术咨询、技术交流、技术转让、技术推广；集成电路芯片及产品销售；智能仪器仪表销售；电力 电子元器件销售；电子元器件零售；电子元器件批发；电子专用材料销售；新能源汽车电附件销售。 截至2024年12月31日，上海胤祺资产总额为2,247.40万元，负债总额为209.68万元，资产净额为2,237.73 万元，2024年度实现营业收入为1,191.89万元，净利润为-309.80万元（经审计）。 截至2024年12月31日，拓维科技资产总额为24,152.41万元，负债总额为5,519.67万元，资产净额为 18,632.74万元，202 ...

Core Points - The announcement confirms the authenticity and completeness of the financial report for the first quarter of 2025, which was approved by the board of directors [2][12][14] - The financial statements are prepared in accordance with Chinese accounting standards and have not been audited [3][4] - The report includes a retrospective adjustment of accounting data due to a change in accounting policy as per the Ministry of Finance's announcement [5] Financial Data - The report indicates that the company has made adjustments to its operating costs and sales expenses for the first quarter of 2024 due to the new accounting interpretation [5] - Non-recurring gains and losses are defined according to the relevant regulations, but specific amounts are not detailed in the provided text [6] - The company has not reported any changes in accounting estimates or corrections of accounting errors [6] Shareholder Information - As of March 31, 2025, all top ten shareholders hold unrestricted shares, and their holdings are consistent across different categories [7][8] - The report notes that there are no preferred shares issued by the company [9] Board and Supervisory Meetings - The board meeting held on April 22, 2025, was conducted via video conference, with a majority of directors present [10][11] - The supervisory board also held a meeting on the same day, confirming the legality and validity of the procedures followed in preparing the financial report [13][14]

截至2024年12月31日，本公司募集资金在银行一般户的存储情况如下： 单位：元 ■ 注1： 截至2024年12月31日，部分公司募集资金已依据既定用途使用完毕并完成销户。 三、本年度募集资金的实际使用情况 （一）募集资金投资项目（以下简称"募投项目"）的资金使用情况 公司2024年度募集资金实际使用情况详见附表1《募集资金使用情况对照表》。 （二）募投项目先期投入及置换情况 截至2021年10月15日（募集资金实际到账日），公司已通过自筹资金进行募集资金投资项目的投资金额 合计为人民币15,911.57万元，具体情况如下： ■ 立信会计师事务所（特殊普通合伙）已对上述自筹资金预先投入募投项目的情况进行了专项审核，并出 具了信会师报字[2021]第ZA15835号《关于宁波德昌电机股份有限公司以自筹资金预先投入募投项目的 鉴证报告》。 公司于2021年12月10日召开第一届董事会第十三次会议、第一届监事会第九次会议，审议通过《关于公 司以募集资金置换预先投入募投项目自筹资金的议案》，同意使用募集资金人民币15,911.57万元置换预 先已投入募投项目的自筹资金。中信证券股份有限公司（以下简称"中信证券"）发表 ...